Evaluation of the effect of Venlafaxine on prevention and treatment of Oxaliplatin-induced peripheral neuropathy in cancer patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160920029889N5

Enrollment

Registered

2024-11-17

Start date

2024-11-30

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal cancer. Malignant neoplasms of digestive organs

Interventions

Intervention 1: Intervention group: Group receiving venlafaxine. Intervention 2: Control group: Group receiving placebo.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age >18 years ALP, AST, ALT 150,000 and WBC > 4,000 receiving chemotherapy regimen containing oxaliplatin (FOLFOX) Absence of peripheral neuropathy at the beginning of the study

Exclusion criteria

Exclusion criteria: Having uncontrolled blood pressure Taking monoamine oxidase inhibitor (MAO-I) drugs at the same time or with an interval of 2 weeks Patients receiving linezolid antibiotic Patients receiving SSRI and SNRI drugs Presence of peripheral neuropathy with other causes (diabetes, thyroid dysfunction, seizure disorder, vitamin B12 deficiency, alcohol abuse and previous history of chemotherapy, etc.) Patients receiving other medications that reduce neuropathy symptoms: antidepressants, anticonvulsants, vitamin (E), glutamine, gabapentin, duloxetine, carbamazepine, phenytoin, valproic acid, lamotrigine, capsaicin cream, lidocaine gel or skin patch, amifostine External factors affecting the quality of life such as the death of first-degree relatives, dismissal from the work environment, unexpected accidents and change of residence.

Design outcomes

Primary

Measure	Time frame
EORTC-QLQCIPN20 questionnaire score. Timepoint: Before receiving the first cycle of chemotherapy, then every month. Method of measurement: EORTC-QLQCIPN20 questionnaire.;NCV test. Timepoint: Before receiving the first cycle of chemotherapy then at the end of the study. Method of measurement: NCV electrode and device.;Depression questionnaire. Timepoint: Before receiving the first cycle of chemotherapy, then every month. Method of measurement: Depression questionnaire.	—

Measure

Time frame

EORTC-QLQCIPN20 questionnaire score. Timepoint: Before receiving the first cycle of chemotherapy, then every month. Method of measurement: EORTC-QLQCIPN20 questionnaire.;NCV test. Timepoint: Before receiving the first cycle of chemotherapy then at the end of the study. Method of measurement: NCV electrode and device.;Depression questionnaire. Timepoint: Before receiving the first cycle of chemotherapy, then every month. Method of measurement: Depression questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfshin Shiva

Oroumia University of Medical Sciences

afshin.shiva@gmail.com+98 44 3275 4991

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026